DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MYRBETRIQ

« Back to Dashboard

Clinical Trials for Myrbetriq

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00410514	A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)	Completed	Astellas Pharma Inc	Phase 2	This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.
NCT00688688	Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder	Completed	Astellas Pharma Inc	Phase 3	The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.
NCT00689104	Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder	Completed	Astellas Pharma Inc	Phase 3	The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
NCT01340027	A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder	Completed	Astellas Pharma Europe B.V.	Phase 2	The purpose of this study is to examine how well two medicines in combination (solifenacin succinate and mirabegron) work in the treatment of bladder problems over a 12-week period.
NCT01638000	A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.	Completed	Astellas Pharma Europe Ltd.	Phase 3	The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of efficacy.

Clinical Trial Conditions for Myrbetriq

Condition Name

Condition Name for Myrbetriq
Intervention	Trials
Overactive Bladder	11
Urinary Bladder, Overactive	5
Urinary Bladder Overactive	4
Urologic Diseases	4

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Myrbetriq
Intervention	Trials
Urinary Bladder, Overactive	18
Urologic Diseases	6
Urinary Bladder Diseases	6
Urinary Incontinence	4

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Myrbetriq

Trials by Country

Trials by Country for Myrbetriq
Location	Trials
United States	189
Canada	37
Denmark	9
Germany	9
United Kingdom	8

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Myrbetriq
Location	Trials
New York	9
California	8
Massachusetts	8
Florida	8
Virginia	7

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Myrbetriq

Clinical Trial Phase

Clinical Trial Phase for Myrbetriq
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	10
Phase 2/Phase 3	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Myrbetriq
Clinical Trial Phase	Trials
Completed	14
Recruiting	12
Not yet recruiting	8

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Myrbetriq

Sponsor Name

Sponsor Name for Myrbetriq
Sponsor	Trials
Astellas Pharma Europe B.V.	7
Astellas Pharma Inc	6
Astellas Scientific & Medical Affairs, Inc.	3

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Myrbetriq
Sponsor	Trials
Industry	23
Other	21
NIH	2

Export unavailable in trial.
Subscribe for complete access.